{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CT+chest%2C+abdomen+and+pelvis&page=2", "query": { "intervention": "CT chest, abdomen and pelvis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 49, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CT+chest%2C+abdomen+and+pelvis&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CT+chest%2C+abdomen+and+pelvis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T03:31:08.049Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05169333", "title": "The Oxford Risk Factors And Non-Invasive Imaging Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiovascular Diseases", "Cardiovascular Risk Factors" ], "interventions": [], "intervention_types": [], "sponsor": "University of Oxford", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 250000, "start_date": "2016-02-23", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-09T03:31:08.049Z", "location_count": 12, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169333" }, { "nct_id": "NCT05825066", "title": "Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreas Adenocarcinoma", "Borderline Resectable Pancreatic Adenocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radiological Assessments", "type": "OTHER" }, { "name": "mFOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2023-08-01", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-09T03:31:08.049Z", "location_count": 2, "location_summary": "Charlotte, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05825066" }, { "nct_id": "NCT04840615", "title": "Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "LMB-100", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "FDG-PET", "type": "DIAGNOSTIC_TEST" }, { "name": "CT CAP", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "Echocardiogram", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 2, "start_date": "2021-06-11", "completion_date": "2022-01-12", "has_results": true, "last_update_posted_date": "2024-02-02", "last_synced_at": "2026-10-09T03:31:08.049Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840615" }, { "nct_id": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Chronic Lymphocytic Lymphoma", "B-Cell Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Magrolimab", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone/prednisolone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "CT Scan chest/abdomen/pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "18-FDG-PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2021-12-16", "completion_date": "2024-06-20", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-09T03:31:08.049Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04599634" }, { "nct_id": "NCT05371054", "title": "Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Non-Hodgkin Lymphoma", "NHL", "Hematologic Malignancies", "Lymphoid Malignancies" ], "interventions": [ { "name": "Vysis LSI MYC Break Apart Rearrangement Probe Kit", "type": "DEVICE" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "VIP152", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "CT neck chest, abdomen, and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone marrow aspiration/Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2023-04-05", "completion_date": "2025-12-16", "has_results": true, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-09T03:31:08.049Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05371054" }, { "nct_id": "NCT05507541", "title": "TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent ALK Positive Large B-Cell Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Intravascular Large B-Cell Lymphoma", "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory ALK Positive Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory Intravascular Large B-Cell Lymphoma", "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Recurrent Gray Zone Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ontorpacept", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Maplirpacept", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2023-04-19", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-09T03:31:08.049Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Rochester, Minnesota", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05507541" }, { "nct_id": "NCT07417488", "title": "GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Small Bowel Adenocarcinoma" ], "interventions": [ { "name": "Ad5.F35-hGUCY2C-PADRE vaccine", "type": "BIOLOGICAL" }, { "name": "Lm-GUCY2C vaccine", "type": "BIOLOGICAL" }, { "name": "CT Scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-04-21", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-09T03:31:08.049Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07417488" }, { "nct_id": "NCT04538378", "title": "Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "EGFR-Mutated Non-Small-Cell Lung Carcinoma", "Small Cell/Neuroendocrine" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor biopsy", "type": "PROCEDURE" }, { "name": "CT chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-07-07", "completion_date": "2024-02-27", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-09T03:31:08.049Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04538378" }, { "nct_id": "NCT01984892", "title": "Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Squamous Cell Carcinoma of the Head and Neck", "Squamous Cell Carcinoma of the Skin", "Sarcoma of the Skin", "Basal Cell Cancer of the Skin", "Breast Cancer" ], "interventions": [ { "name": "Poly-ICLC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nina Bhardwaj", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 8, "start_date": "2013-11", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-10-09T03:31:08.049Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01984892" }, { "nct_id": "NCT05907746", "title": "Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "GATA2", "Immunodeficiency" ], "interventions": [ { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Post-Transplant Cyclophosphamide", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Hematopoietic Cell Transplant", "type": "PROCEDURE" }, { "name": "Briquilimab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "2D echo", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "PFT's", "type": "PROCEDURE" }, { "name": "CT scan of chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "6 Years to 70 Years" }, "enrollment_count": 13, "start_date": "2023-11-29", "completion_date": "2028-07-31", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-09T03:31:08.049Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05907746" } ] }